Molecular Partners Reports Nine Active Trial Sites And Ongoing Treatment In Phase 2 MP0317 Cholangiocarcinoma Study, With Data Update Expected In 2027 And Completion In 2028

Molecular Partners AG Sponsored ADR

Molecular Partners AG Sponsored ADR

MOLN

0.00
  • Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoing
  • Data update expected in 2027, with trial completion in 2028
  • Trial-in-progress poster to be presented at ESMO 2026 in October
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.